Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice
Abstract Chronic kidney disease is a life‐threatening disease worldwide. PPARα is a crucial transcriptional regulator of lipid metabolism and inflammation. Here, we examine whether a novel selective PPARα modulator, pemafibrate modulates renal injury in a model of unilateral ureteral obstruction (UU...
Saved in:
| Main Authors: | Kunihiko Takahara, Noriyuki Ouchi, Tomonobu Takikawa, Yuta Ozaki, Lixin Fang, Hiroshi Kawanishi, Minako Tatsumi, Yoshimitsu Yura, Katsuhiro Kato, Mikito Takefuji, Toyoaki Murohara, Koji Ohashi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Physiological Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.14814/phy2.70135 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pemafibrate modulates peroxisome proliferator-activated receptor alpha and prevents alcohol-associated liver disease in rats
by: Takashi Saito, et al.
Published: (2025-04-01) -
Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01) -
Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice
by: Tomoyo Hara, et al.
Published: (2025-07-01) -
Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data
by: Aki Okamoto, et al.
Published: (2025-02-01) -
Effect of pemafibrate in reducing intestinal long-chain fatty acid absorption and hepatic fibrosis in metabolic dysfunction-associated steatohepatitis rats
by: Masaya Okada, et al.
Published: (2025-05-01)